Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Kearns

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
The Lancet. Psychiatry|August 23, 2015
Improved identification of people at risk of psychosis: is it value for money?Ben Kearns
Pharmacoeconomics|October 5, 2013
Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisalLesley Uttley, Ben Kearns, Shijie Ren, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 6, 2022
Optimizing the Design of a Repeated Fecal Immunochemical Test Bowel Cancer Screening Programme With a Limited Endoscopy Capacity From a Health Economic PerspectiveSophie Whyte, Chloe Thomas, Jim Chilcott, et al.
Pharmacoeconomics|November 26, 2019
How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost EffectivenessBen Kearns, John Stevens, Shijie Ren, et al.
Pharmacoeconomics|April 13, 2013
Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisalBen Kearns, Myfanwy Lloyd Jones, Matt Stevenson, et al.
BMC Medicine|February 5, 2017
Erratum to: Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluationBen Kearns, Jim Chilcott, Sophie Whyte, et al.
BMC Research Notes|July 9, 2014
Predicting preference-based utility values using partial proportional odds modelsRoberta Ara, Ben Kearns, Ben A vanHout, et al.
BMC Medicine|December 7, 2016
Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluationBen Kearns, Jim Chilcott, Sophie Whyte, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 20, 2023
A Systematic Review and Statistical Analysis of Factors Influencing the Cost-Effectiveness of Transcatheter Aortic Valve Implantation for Symptomatic Severe Aortic StenosisLaura Heathcote, Tushar Srivastava, Archita Sarmah, et al.
British Journal of Cancer|October 17, 2023
The cost-effectiveness of risk-stratified breast cancer screening in the UKHarry Hill, Ben Kearns, Nora Pashayan, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The Lancet. Psychiatry|August 23, 2015
Improved identification of people at risk of psychosis: is it value for money?Ben Kearns
Pharmacoeconomics|October 5, 2013
Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisalLesley Uttley, Ben Kearns, Shijie Ren, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 6, 2022
Optimizing the Design of a Repeated Fecal Immunochemical Test Bowel Cancer Screening Programme With a Limited Endoscopy Capacity From a Health Economic PerspectiveSophie Whyte, Chloe Thomas, Jim Chilcott, et al.
Pharmacoeconomics|November 26, 2019
How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost EffectivenessBen Kearns, John Stevens, Shijie Ren, et al.
Pharmacoeconomics|April 13, 2013
Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisalBen Kearns, Myfanwy Lloyd Jones, Matt Stevenson, et al.
BMC Medicine|February 5, 2017
Erratum to: Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluationBen Kearns, Jim Chilcott, Sophie Whyte, et al.
BMC Research Notes|July 9, 2014
Predicting preference-based utility values using partial proportional odds modelsRoberta Ara, Ben Kearns, Ben A vanHout, et al.
BMC Medicine|December 7, 2016
Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluationBen Kearns, Jim Chilcott, Sophie Whyte, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 20, 2023
A Systematic Review and Statistical Analysis of Factors Influencing the Cost-Effectiveness of Transcatheter Aortic Valve Implantation for Symptomatic Severe Aortic StenosisLaura Heathcote, Tushar Srivastava, Archita Sarmah, et al.
British Journal of Cancer|October 17, 2023
The cost-effectiveness of risk-stratified breast cancer screening in the UKHarry Hill, Ben Kearns, Nora Pashayan, et al.
Pageof 3